Industry
Beam's Gene-Edited Sickle Cell Therapy Hits Primary Trial Goal
Beam Therapeutics announced Nov. 10 that its BEACON study of risto-cel, a one-time gene-edited cell therapy for sickle cell disease, met its primary efficacy endpoint: freedom from severe vaso-occlusive crises for at least 12 consecutive months. As of an Oct. 20 data cutoff, 49 patients (39 adults and 10 adolescents) had received the therapy, with 31 completing the required follow-up. The trial also met all primary safety endpoints and secondary efficacy endpoints, though Beam did not disclose the percentage of patients achieving the primary endpoint. Beam expects to submit a biologics license application to the FDA as early as the end of 2026, with detailed pivotal results to be presented at a 2027 medical meeting.
Why it mattersState Medicaid agencies and managed care plans, which cover a large share of sickle cell disease patients, may need to begin planning for coverage and payment pathways for a potential new high-cost gene therapy ahead of an anticipated FDA submission.